Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes

R. Aronson, P. A. Gottlieb, J. S. Christiansen, T. W. Donner, E. Bosi, B. W. Bode, P. Pozzilli

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)S72
JournalDiabetes Technology and Therapeutics
Publication statusPublished - Feb 1 2016

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this